<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02389062</url>
  </required_header>
  <id_info>
    <org_study_id>14D.389</org_study_id>
    <nct_id>NCT02389062</nct_id>
  </id_info>
  <brief_title>Noninvasive Markers of Gluten Ingestion in Celiac Disease Patients</brief_title>
  <official_title>Noninvasive Markers of Gluten Ingestion in Celiac Disease Patients: Prospective, Randomized,Placebo Controlled, Double Blind Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a clinical trial to evaluate the sensitivity of noninvasive, novel markers of gluten
      ingestion in celiac disease patients who are following gluten free diet for at least a period
      of one year. These noninvasive markers may be helpful to monitor the silent intestinal
      damage, possibly resulting from the accidental consumption of gluten due to cross
      contamination of gluten free diet.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The gold-standard for monitoring of dietary adherence is consultation with an expert
      dietitian, but this may be time-consuming for patients and local expertise may not be
      available. Intestinal biopsy is the only direct method to document mucosal healing and can be
      considered in all adults with celiac disease. Non-invasive assessment of compliance with a
      gluten free diet(GFD) can be achieved with monitoring of IgA antibodies to tissue
      transglutaminase (IgA-tTG) or deamidated gliadin peptides, as these markers improve with
      gluten elimination. However, intestinal mucosal damage is present in a significant number of
      patients who report compliance with a gluten free diet and have normalized serology,
      potentially due to dietary lapses or unrecognized contamination with gluten. Furthermore,
      serologic testing may be normal in patients with partial adherence. Patient reported surveys
      show promise for assessing gluten free diet adherence, but further studies are needed.

      Intestinal fatty acid-binding protein (I-FABP), a small (15 kD) cytosolic protein found
      exclusively in the small bowel enterocytes, has been studied as a marker of intestinal
      epithelial damage in septic shock and mesenteric ischemia. More recently, elevated levels of
      intestinal fatty acid-binding protein( I-FABP) have been described as a marker of intestinal
      injury in both adults and children with celiac disease. Intestinal fatty acid binding
      protein, (I-FABP) levels have been shown to significantly correlate with the degree of
      villous atrophy and IgA antibody to tissue transglutaminase (IgA-tTG), as well as decrease
      upon treatment with a gluten free diet(GFD). Incomplete normalization of intestinal fatty
      acid binding protein(I-FABP) on a gluten free diet points to ongoing intestinal injury, even
      in the absence of circulating antibodies, thus suggesting its potential as a non-invasive
      marker for gluten free diet adherence and intestinal damage in celiac disease.

      The measurement of gluten immunogenic peptides (GIP) in stool is a novel method to monitor
      gluten free diet compliance. Recently, a technique to detect gliadin 33-mer equivalent
      peptide epitopes (33EPs) in the stool of pediatric patients has been described. These
      peptides show significant resistance to digestion and were detected in healthy individuals
      after normal gluten-containing diet ingestion. Importantly, these peptides are not detected
      in patients on a gluten free diet, and there appears to be a correlation between the amount
      of gluten intake and the peptide levels. A similar test has been developed for gluten
      intestinal peptide(GIP) detection in urine, although there are currently no peer-reviewed
      studies examining this technique. Further research on the utility of stool and urine gluten
      intestinal peptide (GIP)for monitoring of gluten free diet (GFD) adherence is warranted.

      Given the lack of a non-invasive and accurate measure of gluten intake in celiac disease
      (CD), the investigators will investigate the effect of gluten intake in celiac disease (CD)
      patients using a variety of markers. Patients who are symptom-free on a gluten free diet
      (GFD) will be exposed to various amounts of gluten. Factors that will be studied include the
      effect on patient estimated gluten intake, Celiac disease symptoms, IgA-tTG level,intestinal
      fatty acid binding protein( I-FABP) level, and both stool and urine gluten peptide levels.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1) Change in the patient estimated gluten intake after administration of study pills using the Celiac Dietary Adherence Test (CDAT), to be assessed at the end of follow up week 12</measure>
    <time_frame>up to follow up week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>2) Change in the Celiac disease symptoms, using the Celiac Symptom Index (CSI) after administration of study pills; to be assessed at the end of follow up week 12</measure>
    <time_frame>up to follow up week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>3)Change in IgA antibody to tissue transglutaminase (IgA-TTG) levels after administration of study pills, to be assessed at the end of follow up week 12.</measure>
    <time_frame>up to follow up week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>4) Change in Intestinal fatty acid binding protein (I-FABP) levels after administration of study pills, to be assessed at the end of follow up week 12.</measure>
    <time_frame>up to follow up week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>5)Change in stool gluten intestinal peptide (GIP) level after administration of study pills, to be assessed at the end of follow up week 12</measure>
    <time_frame>up to follow up week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>6)Change in urine gluten intestinal peptide (GIP) level after administration of study pills,to be assessed at the end of follow up week 12</measure>
    <time_frame>up to follow up week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>7)Change in patient estimated gluten intake(PEGI) after administration of study pills, using separate questionnaire, to be assessed at the end of follow up week 12</measure>
    <time_frame>up to follow up week 12</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Adult Form of Celiac Disease</condition>
  <arm_group>
    <arm_group_label>Placebo controlled group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a group of same number of subjects as in other arms, who will be given equivalent dose of placebo- cornstarch capsules i.e 5 capsules containing neutral substance- cornstarch(placebo) to be taken daily by mouth for a period of 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose gluten capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group of subjects will be given high dose i.e 2.5 g of gluten containing capsules, 5 capsules to be taken daily by mouth, for a period of 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose gluten capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group of subjects will be given low dose i.e 0.5 g of gluten containing capsules, 5 capsules to be taken daily by mouth, for a period of 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Administration of gluten( food /wheat protein) capsules or placebo(cornstarch) capsules and tests for novel markers will be done at intervals.</intervention_name>
    <description>After administering the capsules for 16 weeks during study periods, patients's blood will be tested for novel markers- Intestinal fatty acid binding protein(I-FABP), stool for gluten intestinal peptide (GIP), urine for gluten intestinal peptide(GIP), patient estimated gluten intake(PEGI), celiac severity index(CSI), Celiac dietary adherence test(CDAT) by standard questionnaire provided during the visits. These tests will be done over a period of 16 weeks and at a follow up 3 months later.</description>
    <arm_group_label>Placebo controlled group</arm_group_label>
    <arm_group_label>High dose gluten capsules</arm_group_label>
    <arm_group_label>Low dose gluten capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  This study population will consist of patients with a prior diagnosis of celiac
             disease based on intestinal biopsy (Marsh score of 1-4) who report control of symptoms
             with adherence to gluten free diet(GFD) for at least one year and have a baseline IgA
             antibody to tissue transglutaminase(IgA-tTG) within the normal range.

        Exclusion Criteria:

          -  Patients &lt; 18 years of age

          -  Patients with refractory celiac disease (RFD), defined as persisting or recurring
             symptoms and mucosal villous atrophy, despite strict adherence to a gluten free diet
             (GFD) for &gt;12 months and a negative IgA antibody to tissue transglutaminase (IgA-tTG)

          -  Patients with enteropathy-associated T-cell lymphoma

          -  Patients with IgA deficiency

          -  Patients with a diagnosis of inflammatory bowel disease, irritable bowel symptoms, or
             acute gastroenteritis

          -  Patients taking immunosuppressive medications

          -  Patients who are pregnant

          -  Patients who are breast feeding/lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony J. DiMarino, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University, Philadelphia, PA 19107</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>CYNTHIA MILLER, RN</last_name>
    <phone>215-955-8108</phone>
    <email>Cynthia.L.Miller.3@jefferson.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia L Miller, RN</last_name>
      <phone>215-955-8108</phone>
      <email>Cynthia.L.Miller.3@jefferson.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ajini Cherian, RN</last_name>
      <phone>215-955-7979</phone>
      <email>Ajini.Cherian@jefferson.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Anthony DiMarino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephanie Moleski, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Colin Smith, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Rubio-Tapia A, Hill ID, Kelly CP, Calderwood AH, Murray JA; American College of Gastroenterology. ACG clinical guidelines: diagnosis and management of celiac disease. Am J Gastroenterol. 2013 May;108(5):656-76; quiz 677. doi: 10.1038/ajg.2013.79. Epub 2013 Apr 23.</citation>
    <PMID>23609613</PMID>
  </reference>
  <reference>
    <citation>Murray JA, Watson T, Clearman B, Mitros F. Effect of a gluten-free diet on gastrointestinal symptoms in celiac disease. Am J Clin Nutr. 2004 Apr;79(4):669-73.</citation>
    <PMID>15051613</PMID>
  </reference>
  <reference>
    <citation>Lee SK, Lo W, Memeo L, Rotterdam H, Green PH. Duodenal histology in patients with celiac disease after treatment with a gluten-free diet. Gastrointest Endosc. 2003 Feb;57(2):187-91.</citation>
    <PMID>12556782</PMID>
  </reference>
  <reference>
    <citation>Rubio-Tapia A, Rahim MW, See JA, Lahr BD, Wu TT, Murray JA. Mucosal recovery and mortality in adults with celiac disease after treatment with a gluten-free diet. Am J Gastroenterol. 2010 Jun;105(6):1412-20. doi: 10.1038/ajg.2010.10. Epub 2010 Feb 9.</citation>
    <PMID>20145607</PMID>
  </reference>
  <reference>
    <citation>Bai JC, Gonzalez D, Mautalen C, Mazure R, Pedreira S, Vazquez H, Smecuol E, Siccardi A, Cataldi M, Niveloni S, Boerr LA, Mauriño E. Long-term effect of gluten restriction on bone mineral density of patients with coeliac disease. Aliment Pharmacol Ther. 1997 Feb;11(1):157-64.</citation>
    <PMID>9042988</PMID>
  </reference>
  <reference>
    <citation>Dickey W. Low serum vitamin B12 is common in coeliac disease and is not due to autoimmune gastritis. Eur J Gastroenterol Hepatol. 2002 Apr;14(4):425-7.</citation>
    <PMID>11943958</PMID>
  </reference>
  <reference>
    <citation>Halfdanarson TR, Kumar N, Hogan WJ, Murray JA. Copper deficiency in celiac disease. J Clin Gastroenterol. 2009 Feb;43(2):162-4. doi: 10.1097/MCG.0b013e3181354294.</citation>
    <PMID>18496230</PMID>
  </reference>
  <reference>
    <citation>Kotze LM. Gynecologic and obstetric findings related to nutritional status and adherence to a gluten-free diet in Brazilian patients with celiac disease. J Clin Gastroenterol. 2004 Aug;38(7):567-74.</citation>
    <PMID>15232359</PMID>
  </reference>
  <reference>
    <citation>Choi JM, Lebwohl B, Wang J, Lee SK, Murray JA, Sauer MV, Green PH. Increased prevalence of celiac disease in patients with unexplained infertility in the United States. J Reprod Med. 2011 May-Jun;56(5-6):199-203.</citation>
    <PMID>21682114</PMID>
  </reference>
  <reference>
    <citation>Khashan AS, Henriksen TB, Mortensen PB, McNamee R, McCarthy FP, Pedersen MG, Kenny LC. The impact of maternal celiac disease on birthweight and preterm birth: a Danish population-based cohort study. Hum Reprod. 2010 Feb;25(2):528-34. doi: 10.1093/humrep/dep409. Epub 2009 Nov 24.</citation>
    <PMID>19939833</PMID>
  </reference>
  <reference>
    <citation>Catassi C, Fabiani E, Iacono G, D'Agate C, Francavilla R, Biagi F, Volta U, Accomando S, Picarelli A, De Vitis I, Pianelli G, Gesuita R, Carle F, Mandolesi A, Bearzi I, Fasano A. A prospective, double-blind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease. Am J Clin Nutr. 2007 Jan;85(1):160-6.</citation>
    <PMID>17209192</PMID>
  </reference>
  <reference>
    <citation>Haines ML, Anderson RP, Gibson PR. Systematic review: The evidence base for long-term management of coeliac disease. Aliment Pharmacol Ther. 2008 Nov 1;28(9):1042-66. doi: 10.1111/j.1365-2036.2008.03820.x. Epub 2008 Jul 30. Review.</citation>
    <PMID>18671779</PMID>
  </reference>
  <reference>
    <citation>Nachman F, Sugai E, Vázquez H, González A, Andrenacci P, Niveloni S, Mazure R, Smecuol E, Moreno ML, Hwang HJ, Sánchez MI, Mauriño E, Bai JC. Serological tests for celiac disease as indicators of long-term compliance with the gluten-free diet. Eur J Gastroenterol Hepatol. 2011 Jun;23(6):473-80. doi: 10.1097/MEG.0b013e328346e0f1.</citation>
    <PMID>21537123</PMID>
  </reference>
  <reference>
    <citation>Lanzini A, Lanzarotto F, Villanacci V, Mora A, Bertolazzi S, Turini D, Carella G, Malagoli A, Ferrante G, Cesana BM, Ricci C. Complete recovery of intestinal mucosa occurs very rarely in adult coeliac patients despite adherence to gluten-free diet. Aliment Pharmacol Ther. 2009 Jun 15;29(12):1299-308. doi: 10.1111/j.1365-2036.2009.03992.x. Epub 2009 Mar 3.</citation>
    <PMID>19302264</PMID>
  </reference>
  <reference>
    <citation>Vahedi K, Mascart F, Mary JY, Laberenne JE, Bouhnik Y, Morin MC, Ocmant A, Velly C, Colombel JF, Matuchansky C. Reliability of antitransglutaminase antibodies as predictors of gluten-free diet compliance in adult celiac disease. Am J Gastroenterol. 2003 May;98(5):1079-87.</citation>
    <PMID>12809831</PMID>
  </reference>
  <reference>
    <citation>Leffler DA, Edwards George JB, Dennis M, Cook EF, Schuppan D, Kelly CP. A prospective comparative study of five measures of gluten-free diet adherence in adults with coeliac disease. Aliment Pharmacol Ther. 2007 Nov 1;26(9):1227-35.</citation>
    <PMID>17944737</PMID>
  </reference>
  <reference>
    <citation>Leffler DA, Dennis M, Edwards George JB, Jamma S, Magge S, Cook EF, Schuppan D, Kelly CP. A simple validated gluten-free diet adherence survey for adults with celiac disease. Clin Gastroenterol Hepatol. 2009 May;7(5):530-6, 536.e1-2. doi: 10.1016/j.cgh.2008.12.032. Epub 2009 Jan 11.</citation>
    <PMID>19268725</PMID>
  </reference>
  <reference>
    <citation>Derikx JP, Poeze M, van Bijnen AA, Buurman WA, Heineman E. Evidence for intestinal and liver epithelial cell injury in the early phase of sepsis. Shock. 2007 Nov;28(5):544-8.</citation>
    <PMID>17607153</PMID>
  </reference>
  <reference>
    <citation>Lieberman JM, Sacchettini J, Marks C, Marks WH. Human intestinal fatty acid binding protein: report of an assay with studies in normal volunteers and intestinal ischemia. Surgery. 1997 Mar;121(3):335-42.</citation>
    <PMID>9068676</PMID>
  </reference>
  <reference>
    <citation>Kanda T, Fujii H, Tani T, Murakami H, Suda T, Sakai Y, Ono T, Hatakeyama K. Intestinal fatty acid-binding protein is a useful diagnostic marker for mesenteric infarction in humans. Gastroenterology. 1996 Feb;110(2):339-43.</citation>
    <PMID>8566578</PMID>
  </reference>
  <reference>
    <citation>Kanda T, Tsukahara A, Ueki K, Sakai Y, Tani T, Nishimura A, Yamazaki T, Tamiya Y, Tada T, Hirota M, Hasegawa J, Funaoka H, Fujii H, Hatakeyama K. Diagnosis of ischemic small bowel disease by measurement of serum intestinal fatty acid-binding protein in patients with acute abdomen: a multicenter, observer-blinded validation study. J Gastroenterol. 2011 Apr;46(4):492-500. doi: 10.1007/s00535-011-0373-2. Epub 2011 Feb 5.</citation>
    <PMID>21298292</PMID>
  </reference>
  <reference>
    <citation>Derikx JP, Vreugdenhil AC, Van den Neucker AM, Grootjans J, van Bijnen AA, Damoiseaux JG, van Heurn LW, Heineman E, Buurman WA. A pilot study on the noninvasive evaluation of intestinal damage in celiac disease using I-FABP and L-FABP. J Clin Gastroenterol. 2009 Sep;43(8):727-33. doi: 10.1097/MCG.0b013e31819194b0.</citation>
    <PMID>19359998</PMID>
  </reference>
  <reference>
    <citation>Vreugdenhil AC, Wolters VM, Adriaanse MP, Van den Neucker AM, van Bijnen AA, Houwen R, Buurman WA. Additional value of serum I-FABP levels for evaluating celiac disease activity in children. Scand J Gastroenterol. 2011 Dec;46(12):1435-41. doi: 10.3109/00365521.2011.627447. Epub 2011 Oct 27.</citation>
    <PMID>22029621</PMID>
  </reference>
  <reference>
    <citation>Adriaanse MP, Tack GJ, Passos VL, Damoiseaux JG, Schreurs MW, van Wijck K, Riedl RG, Masclee AA, Buurman WA, Mulder CJ, Vreugdenhil AC. Serum I-FABP as marker for enterocyte damage in coeliac disease and its relation to villous atrophy and circulating autoantibodies. Aliment Pharmacol Ther. 2013 Feb;37(4):482-90. doi: 10.1111/apt.12194. Epub 2013 Jan 7.</citation>
    <PMID>23289539</PMID>
  </reference>
  <reference>
    <citation>Rodriguez-Herrera A, Comino I, Real A, et al, Monitoring of gluten-free diet compliance in pediatric patients by fecal check; (Abstract #F613). Presented at the 15th International Celiac Disease Symposium. September, 2013. Chicago.</citation>
  </reference>
  <reference>
    <citation>Comino I, Real A, Vivas S, Síglez MÁ, Caminero A, Nistal E, Casqueiro J, Rodríguez-Herrera A, Cebolla A, Sousa C. Monitoring of gluten-free diet compliance in celiac patients by assessment of gliadin 33-mer equivalent epitopes in feces. Am J Clin Nutr. 2012 Mar;95(3):670-7. doi: 10.3945/ajcn.111.026708. Epub 2012 Jan 18.</citation>
    <PMID>22258271</PMID>
  </reference>
  <reference>
    <citation>Leffler DA, Dennis M, Edwards George J, Jamma S, Cook EF, Schuppan D, Kelly CP. A validated disease-specific symptom index for adults with celiac disease. Clin Gastroenterol Hepatol. 2009 Dec;7(12):1328-34, 1334.e1-3. doi: 10.1016/j.cgh.2009.07.031. Epub 2009 Aug 7.</citation>
    <PMID>19665584</PMID>
  </reference>
  <results_reference>
    <citation>Fasano A, Catassi C. Clinical practice. Celiac disease. N Engl J Med. 2012 Dec 20;367(25):2419-26. doi: 10.1056/NEJMcp1113994. Review.</citation>
    <PMID>23252527</PMID>
  </results_reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2015</study_first_submitted>
  <study_first_submitted_qc>March 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2015</study_first_posted>
  <last_update_submitted>March 9, 2015</last_update_submitted>
  <last_update_submitted_qc>March 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Thomas Jefferson University</investigator_affiliation>
    <investigator_full_name>Jeff GI</investigator_full_name>
    <investigator_title>Professor, Chair, Division of Gastroenterology, Director, celiac disease center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celiac Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

